CASG 209

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, double-blind, placebo-controlled, sequential dose escalation study to evaluate the safety, tolerability, maximum tolerance dose, physical affects and preliminary effectiveness of cidofovir in kidney transplant recipients with newly diagnosed BK virus-induced nephropathy (kidney disorder). Cidofovir VISTIDE is a marketed product for cytomegalovirus disease in HIV-infected patients.